Anal cancer

Lore & Background

Anal cancer arises from the anus, the distal opening of the gastrointestinal tract. Symptoms may include bleeding from the anus, a lump near the anus, pain, itchiness, discharge, or a change in bowel movements. Risk factors include human papillomavirus (HPV), HIV/AIDS, receptive anal sex, smoking, and many sexual partners. Diagnosis is suspected based on physical examination and confirmed by tissue biopsy. Most anal cancers are squamous cell carcinomas, arising near the squamocolumnar junction. Other types include adenocarcinoma, lymphoma, sarcoma, or melanoma. Prevention includes avoiding risk factors and HPV vaccination. Standard treatment may include radiation therapy, chemotherapy, and surgery. The number of cases has increased since the 1990s. Women are affected more often than men.

Reader's Guide

Anal cancer represents about 0.5% of new cancers in the United States, with about 10,930 people diagnosed per year. Onset is typically after age 45, and women are affected more often than men. The five-year survival rate in the United States is 71%. The disease is strongly linked to HPV, with studies showing high-risk types of HPV, notably HPV-16, detected in 84% of anal cancer specimens. Smoking is an independent risk factor, with current smokers having a fourfold increase in risk. Current gold-standard therapy is combined chemotherapy and radiation, which has improved preservation of the anal sphincter and quality of life. The HPV vaccine, approved in the US in 2010 for males and females aged 9 to 26, is used to prevent anal cancer and precancerous lesions. Screening with anal Pap smears has been studied for high-risk individuals, including HIV-positive men and women with a history of cervical cancer.

Did You Know?

• About 10,930 people are diagnosed with anal cancer per year in the United States, representing about 0.5% of new cancers.
• High-risk types of HPV, notably HPV-16, were detected in 84% of anal cancer specimens examined in one study.
• Current smokers are several times more likely to develop anal cancer compared with nonsmokers, with a fourfold increase in risk.
• The five-year survival rate for anal cancer in the United States is 71%.

Etiology and Risk Factors

Anal cancer is most commonly linked to human papillomavirus infection. Research from Denmark and Sweden revealed that the HPV strains responsible for high-risk cervical cancer also appear in a large proportion of anal cancer specimens. One study identified high-risk HPV types, particularly HPV-16, in roughly 84 percent of examined tumor samples. Based on the Scandinavian data, researcher Parkin estimated that approximately 90 percent of anal cancers can be attributed to HPV. Beyond viral infection, sexual behavior plays a notable role; having multiple partners and engaging in receptive anal intercourse elevates risk for both men and women due to greater HPV exposure. Smoking is another significant independent factor. Epidemiologist Janet Daling and her team at Fred Hutchinson found that current smokers face roughly a fourfold increase in risk, with more than half of diagnosed patients being active smokers at the time of diagnosis, compared to about 23 percent in control groups. The mechanism remains unclear but may involve disruption of apoptosis or immune suppression. Additionally, immunosuppression associated with HIV infection, a prior history of cervical, vaginal, or vulvar cancers, and a rare embryological remnant called cloacogenic carcinoma (accounting for 2 to 3 percent of anorectal cancers, more common in women) all contribute to the broader risk landscape.

Clinical Presentation and Diagnosis

Anal cancer typically manifests through a constellation of local symptoms. Patients may notice rectal bleeding, which can be severe, a palpable lump near the anal opening, persistent pain or pressure in the anorectal region, itching, or unusual discharge. Changes in bowel habits are also a recognized warning sign. Because these symptoms can overlap with benign conditions, diagnosis relies on careful physical examination followed by tissue biopsy for histological confirmation. The vast majority of cases are squamous cell carcinomas arising near the squamocolumnar junction, though adenocarcinoma, lymphoma, sarcoma, melanoma, and the rare cloacogenic carcinoma also occur. Once confirmed, pathologists assign a TNM stage. The primary tumor is graded from Tis (high-grade intraepithelial lesion) through T4 (invasion into adjacent organs such as the vagina, urethra, or bladder), with size thresholds at 2 and 5 centimeters. Regional lymph node involvement is categorized by location—inguinal, mesorectal, internal iliac, or external iliac—while distant metastasis is simply recorded as M1. This staging framework guides treatment decisions and prognostication.

Prevention and Screening

Because the overwhelming majority of anal cancers stem from HPV infection, vaccination represents the most promising preventive strategy. In 2010, the U.S. approved Gardasil for the prevention of anal cancer and precancerous lesions in both males and females aged nine to twenty-six. In HPV-naive women under twenty-six, the vaccine's efficacy against types 16 and 18 ranges from 91 to 100 percent, though effectiveness drops to about 76 percent when administered regardless of prior infection. Beyond vaccination, avoiding known behavioral risk factors such as smoking, multiple sexual partners, and receptive anal intercourse remains important. As case numbers have climbed since the 1990s, screening for anal intraepithelial neoplasia has grown in importance for at-risk populations. Anal Pap smears, modeled on cervical cancer screening, have been studied for early detection. In 2011, an HIV clinic launched a program where nurse practitioners performed anal Pap screening on HIV-positive men; abnormal results led to high-resolution anoscopy, and many precancerous growths were identified and safely removed. A parallel study in women with prior cervical cancer or high-grade cervical intraepithelial neoplasia found that over 30 percent had abnormal anal Pap results, with one-third already showing anal intraepithelial neoplasia.

Treatment and Prognosis

For localized disease, standard treatment typically combines radiation therapy and chemotherapy, with surgery reserved for specific circumstances. The therapeutic approach depends heavily on the TNM stage established at diagnosis. In the United States, approximately 10,930 new cases are diagnosed each year, accounting for roughly 0.5 percent of all new cancers. The disease predominantly affects individuals over the age of forty-five, and women are diagnosed more frequently than men. A concerning trend is the steady rise in incidence since the 1990s. Despite the seriousness of the diagnosis, the five-year survival rate in the United States stands at 71 percent, a figure that likely reflects the effectiveness of the chemoradiation protocol for squamous cell histology and the importance of early detection. The combination of HPV vaccination for younger populations, targeted screening for high-risk groups such as HIV-positive individuals and those with prior gynecologic cancers, and avoidance of modifiable risk factors like smoking collectively offer the best chance of reducing both incidence and mortality going forward.